Abstract Learning Objectives After completing this course, the reader should be able to:
Evaluate the recommended clinical doses and the associated safety data for targeted …

Advances in medical oncology has led cancer patients to live longer. Moreover, the field of
molecular oncology is rapidly evolving, new therapies emerge, and drugs are approved …

An exciting era in the diagnosis and treatment of cancer has emerged in the last 2 decades.
What was once an often deadly disease has, for many patients, become a chronic disease …

The advent of targeted agents for the treatment of advanced renal cell carcinoma has led to
dramatic improvements in therapy. However, the chronic use of these medications has also …

Results Mean follow-up was 6 years (25th and 75th percentiles, 4 and 9 years). AKI
occurred in 31.5% of patients, with a median initial decline in eGFR of 10 ml/min per 1.73 m …

With seven agents approved for metastatic renal cell carcinoma (RCC) within the past few
years, there has undoubtedly been progress in treating this disease. The treatment safety of …

Anticancer drug-induced kidney disease is a problem commonly encountered by
nephrologists. The number of medications employed by oncologists causing acute and …

Monitoring renal function in patients with solid tumors and hematologic malignancies is vital
to the safe administration of therapeutic agents. Renal impairment is frequent in elderly …

VEGF and mTOR inhibitors have encouraging clinical activity for patients with advanced
renal cell carcinoma (RCC), but may lead to significant short-and long-term toxicities …

Background Nephrotoxicity is the dose-limiting side effect of cisplatin justifying the
assessment of renal function for dose adjustment. Objective To determine whether …